HCA Healthcare (HCA) Expected to Announce Earnings on Friday

HCA Healthcare (NYSE:HCA) is projected to post its quarterly earnings results before the market opens on Friday, January 24th. Analysts expect HCA Healthcare to post earnings of $6.03 per share and revenue of $18,234,322.79 billion for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

HCA Healthcare Stock Performance

Shares of HCA opened at $309.26 on Friday. The company has a debt-to-equity ratio of 48.71, a current ratio of 1.12 and a quick ratio of 1.00. The stock has a market capitalization of $78.34 billion, a P/E ratio of 13.89, a P/E/G ratio of 1.03 and a beta of 1.64. HCA Healthcare has a 12-month low of $276.50 and a 12-month high of $417.14. The firm’s 50 day moving average is $318.49 and its 200-day moving average is $353.11.

HCA Healthcare Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, December 27th. Investors of record on Friday, December 13th were issued a $0.66 dividend. This represents a $2.64 dividend on an annualized basis and a dividend yield of 0.85%. The ex-dividend date was Friday, December 13th. HCA Healthcare’s payout ratio is 11.85%.

Insiders Place Their Bets

In other HCA Healthcare news, SVP Phillip G. Billington sold 3,897 shares of the business’s stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $350.00, for a total transaction of $1,363,950.00. Following the completion of the transaction, the senior vice president now owns 52,702 shares of the company’s stock, valued at $18,445,700. The trade was a 6.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of HCA Healthcare stock in a transaction dated Thursday, November 14th. The stock was sold at an average price of $353.00, for a total value of $1,023,700.00. Following the completion of the transaction, the insider now owns 6,843 shares in the company, valued at $2,415,579. The trade was a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

Analysts Set New Price Targets

HCA has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $392.00 price target on shares of HCA Healthcare in a research note on Tuesday, October 1st. Wells Fargo & Company lowered shares of HCA Healthcare from an “equal weight” rating to an “underweight” rating and cut their price target for the company from $400.00 to $320.00 in a report on Monday, November 25th. Truist Financial cut their target price on shares of HCA Healthcare from $430.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Raymond James downgraded HCA Healthcare from an “outperform” rating to a “market perform” rating in a report on Friday, November 22nd. Finally, TD Cowen decreased their price objective on HCA Healthcare from $450.00 to $440.00 and set a “buy” rating for the company in a research report on Monday, October 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $385.27.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.